IP Library › Granted Patent US 8,017,403
Granted Patent B2
US 8,017,403 · App. 11/763,380 · Granted Sep 13, 2011

Mass spectrometry method for measuring vitamin B6 in body fluid

Assignee: Quest Diagnostics Investments Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,017,403
App. No.
11/763,380
Granted
Sep 13, 2011
Kind
B2
Abstract

Provided are methods of detecting the presence or amount of the active form of vitamin B6, pyridoxal 5′-phosphate, in a body fluid sample using tandem mass spectrometry coupled with liquid chromatography.

Claims (44)

1. A method for detecting the presence or amount of pyridoxal 5′-phosphate in a body fluid sample by tandem mass spectrometry, comprising:

purifying said sample, wherein purifying comprises:

(a) applying said sample to an extraction column under turbulent flow conditions whereby pyridoxal 5′-phosphate is reversibly retained by the extraction column, wherein said extraction column comprises particles with an average diameter of between about 35 μm and about 50 μm;

(b) washing the extraction column under conditions whereby non-retained materials from the sample are washed from the column;

(c) eluting retained pyridoxal 5′-phosphate from the extraction column;

(d) applying the eluted pyridoxal 5′-phosphate from the extraction column to an analytical column under laminar flow conditions; and

(e) eluting pyridoxal 5′-phosphate from the analytical column;

(ii) generating a parent ion of said pyridoxal 5′-phosphate from said purified sample;

(iii) generating one or more daughter ions of said parent ion; and

(iv) detecting the presence or amount of one or more said ions generated in step (ii) or step (iii) or both, and relating the detected ions to the presence or amount of said pyridoxal 5′-phosphate in said body fluid sample.

2. The method of claim 1 , wherein the extraction column is a mixed mode anion exchange polymer column, and the analytical column is a C-8 analytical column.

3. The method of claim 2 , wherein the extraction column comprises particles of about 50 μm, and the analytical column comprises particles of about 3.5 μm.

4. The method of claim 1 , wherein steps (a)-(e) are performed in an online automated fashion.

5. The method of claim 4 , wherein steps (ii)-(iv) are performed in an online automated fashion with steps (a)-(e).

6. The method of claim 1 , wherein said parent ion has a mass/charge ratio of 248.03 +/−1.

7. The method of claim 6 , wherein said one or more daughter ions comprise a daughter ion with a mass/charge ratio of 150.00 +/−1.

8. The method of claim 1 , wherein said sample is plasma.

9. The method of claim 1 , wherein step (ii) is performed by electrospray ionization.

10. The method of claim 1 , wherein an internal standard is added to the body fluid sample prior to step (i).

11. The method of claim 10 , wherein the internal standard is 2-hydroxy-6-methylpyridine-3-carboxylic acid.

12. The method of claim 11 , wherein the parent ion of the internal standard generated in step (ii) has a mass to charge ratio of 154.04 +/−1.

13. The method of claim 11 , wherein the daughter ion of the internal standard generated in step (iii) has a mass to charge ratio of 136.00 +/−1.

14. The method of claim 1 , wherein said extraction column is a turbulent flow liquid chromatography column.

15. The method of claim 1 , wherein said analytical column is a high performance liquid chromatography (HPLC) column.

16. A method for detecting the amount of pyridoxal 5′-phosphate in a body fluid sample by tandem mass spectrometry, comprising:

(i) purifying said sample, wherein purifying comprises:

(a) applying said sample to a turbulent flow liquid chromatography column under conditions whereby pyridoxal 5′-phosphate is reversibly retained;

(b) washing the turbulent flow liquid chromatography column under conditions whereby non-retained materials from the sample are washed from the column;

(c) eluting retained pyridoxal 5′-phosphate from the turbulent flow liquid chromatography column;

(d) applying the eluted pyridoxal 5′-phosphate to a high performance liquid chromatography (HPLC) column; and

(e) eluting pyridoxal 5′-phosphate from the HPLC column;

(ii) generating a parent ion of said pyridoxal 5′-phosphate from said purified sample;

(iii) generating one or more daughter ions of said parent ion; and

(iv) detecting the presence or amount of one or more said ions generated in step (ii) or step (iii) or both, and relating the detected ions to the presence or amount of said pyridoxal 5′-phosphate in said sample.

17. The method of claim 16 , wherein the turbulent flow liquid chromatography column is a mixed mode anion exchange polymer column, and the HPLC column is a C-8 analytical column.

18. The method of claim 17 , wherein the turbulent flow liquid chromatography column comprises particles of about 50 μm, and the HPLC column comprises particles of about 3.5 μm.

19. The method of claim 18 , wherein said parent ion has a mass/charge ratio of 248.03 +/−1.

20. The method of claim 19 , wherein said one or more daughter ions comprise a daughter ion with a mass/charge ratio of 150.00 +/−1.

21. The method of claim 16 , wherein said sample is plasma.

22. The method of claim 16 , wherein step (ii) is performed by electrospray ionization.

23. The method of claim 16 , wherein an internal standard is added to the body fluid sample prior to step (i).

24. The method of claim 23 , wherein the internal standard is 2-hydroxy-6-methylpyridine-3-carboxylic acid.

25. The method of claim 24 , wherein the parent ion of the internal standard generated in step (ii) has a mass to charge ratio of 154.04 +/−1.

26. The method of claim 24 , wherein the daughter ion of the internal standard generated in step (iii) has a mass to charge ratio of 136.00 +/−1.

Assignments (3)
ENTITY CONVERSION Recorded Oct 25, 2024
From: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
To: QUEST DIAGNOSTICS INVESTMENTS LLC
Reel/Frame 069238/0375 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2011
From: JIANG, QIBO; CHAN, SUM; REITZ, RICHARD
To: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
Reel/Frame 026738/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2007
From: JIANG, QIBO; CHAN, SUM; REITZ, RICHARD
To: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
Reel/Frame 019971/0084 →
Continuity (1)
Related Publication 20080311671A1 · Dec 18, 2008